백신 수탁제조 시장 : 산업 동향 및 세계 예측(-2035년) - 발현 시스템 유형별, 기업 규모별, 지역별

Vaccine Contract Manufacturing Market: Industry Trends and Global Forecasts, till 2035: Type of Expression System Used, Company Size and Geographical Regions

US $ 4,799 ￦ 6,943,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 10,126,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 15,335,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 26,042,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

백신 수탁제조 시장 규모는 2024년 23억 8,000만 달러에 달할 것으로 예상되며, 2024-2035년 예측 기간 동안 연평균 6.5%의 성장률을 기록할 것으로 예상됩니다.

다양한 감염병, 종양, 자가면역질환을 표적으로 하는 백신 파이프라인이 증가함에 따라 백신 수탁제조에 대한 수요가 증가하고 있습니다. 수탁 제조업체는 특히 mRNA 및 바이러스 벡터와 같은 특수 백신에 대해 제약회사에 대규모 제조 서비스를 제공하고 있습니다. 백신은 심각한 질병을 예방하는 데 중요한 역할을 하고 있으며, 최근 백신 기술의 발전은 중요한 이정표가 되고 있습니다. 호흡기세포융합바이러스(RSV)와 티쿤구니야에 대한 최초의 백신 등 FDA가 승인한 수많은 백신의 승인은 백신의 새로운 시대로의 전환을 시사하고 있습니다.

백신에 대한 수요가 증가함에 따라 백신 전문 위탁생산기관(CMO)의 사업 기회도 확대되고 있으며, 2000년 이후 130개 이상의 백신 CMO가 설립되었으며, 이는 위탁생산업체들의 시장 확대를 반영하고 있습니다. CMO들은 경쟁력을 유지하기 위해 최첨단 도구와 기술에 투자하고, 증가하는 백신 수요에 대응할 수 있는 역량과 능력을 확장하고 있습니다.

아웃소싱은 백신 산업에서 실행 가능하고 수익성 있는 비즈니스 모델로 받아들여지고 있으며, 세계 백신 수탁제조 시장의 성장을 주도하고 있습니다. 또한, 백신 보조제 기업들이 백신 개발 및 제조업체를 위한 혁신적인 보조제를 개발하고 있는 것도 이 시장의 성장을 촉진하고 있습니다.

이 보고서는 세계 백신 수탁제조 시장에 대해 조사했으며, 시장 개요와 함께 사용되는 발현 시스템 유형별, 기업 규모별, 지역별 동향 및 향후 시장 전망 등을 제공합니다.

목차

제1장 서문

제2장 조사 방법

제3장 경제 및 기타 프로젝트 특유의 고려사항

제4장 주요 요약

제5장 소개

• 분석 개요
• 유효 성분 종류별 백신 분류
• 백신 제제의 주요 성분
• 백신 개발과 제조
• 백신 수탁제조
• 향후 전망

제6장 시장 상황

• 분석 개요
• 백신 수탁 제조업체 : 시장 상황

제7장 기업 경쟁력 분석

• 분석 개요
• 가정과 주요 파라미터
• 조사 방법
• 기업 경쟁력 분석 : 북미의 백신 수탁 제조업체
• 기업 경쟁력 분석 : 유럽의 백신 수탁 제조업체
• 기업 경쟁력 분석 : 아시아태평양의 백신 수탁 제조업체
• 기업 경쟁력 분석 : 기타 지역의 백신 수탁 제조업체

제8장 기업 개요 : 북미의 백신 수탁 제조업체

• 분석 개요
• AGC Biologics
• Bioreliance
• Catalent
• Charles River Laboratories
• Curia
• Meridian Life Science

제9장 기업 개요 : 유럽의 백신 수탁 제조업체

• 분석 개요
• Boehringer Ingelheim BioXcellence
• Eurofins Amatsigroup
• Eurogentec
• IDT Biologika
• Lonza

제10장 기업 개요 : 아시아태평양의 백신 수탁 제조업체

• 분석 개요
• Bharat Biotech
• Biological E
• GreenPak Biotech
• Hong Kong Institute of Biotechnology
• Syngene International
• Wockhardt
• WuXi Biologics

제11장 파트너십과 협업

제12장 최근의 확장

제13장 인수합병

제14장 용량 분석

제15장 수요 분석

제16장 벤더 선택 프레임워크 분석

제17장 세계의 백신 수탁제조 시장

• 분석 개요
• 주요 가정과 조사 방법
• 세계의 백신 수탁제조 시장, 실적(2018-2023년) 및 예측(2024-2035년)
• 주요 시장 세분화
• 세계의 COVID-19 수탁제조 시장, 실적(2018-2023년) 및 예측(2024-2035년)

제18장 세계의 백신 수탁제조 시장(사용되는 발현 시스템 유형별)

제19장 세계의 백신 수탁제조 시장(기업 규모별)

제20장 세계의 백신 수탁제조 시장(지역별)

제21장 향후 성장 기회

• 분석 개요
• 백신 제조 업계 성장을 촉진하는 기술의 진보
• 백신 제조의 일회용 시스템과 컴포넌트로의 이동
• 바이러스 유사 입자(VLP)의 출현
• 기존 인프라에 대한 투자 증가
• 진화하는 클라이언트/스폰서와 CMO/CDMO의 관계
• 사업 인수 및 통합 활동

제22장 SWOT 분석

제23장 결론

제24장 이그제큐티브 인사이트

제25장 부록 2 : 표형식 데이터

제26장 부록 II : 기업 및 단체 리스트

ksm

영문 목차

영문목차

The Vaccine Contract Manufacturing Market is valued at USD 2.38 billion in 2024 growing at a CAGR of 6.5% during the forecast period 2024-2035.

The demand for vaccine contract manufacturing is increasing, driven by the growing pipeline of vaccines targeting various infectious diseases, oncological and autoimmune disorders. Contract manufacturers provide large-scale production services to pharmaceutical companies, particularly for specialized vaccines like mRNA and viral vectors. Vaccines play a critical role in preventing serious illnesses, and recent advancements in vaccine technology have marked significant milestones. The approval of numerous FDA-approved vaccines, including the first vaccine for respiratory syncytial virus (RSV) and chikungunya, signals a shift towards a new era of vaccines.

As the demand for vaccines grows, opportunities for contract manufacturing organizations (CMOs) specializing in vaccines are expanding. Since 2000, over 130 vaccine CMOs have been established, reflecting the market expansion of contract service providers. To stay competitive, CMOs are investing in cutting-edge tools and technologies, expanding their capacities and capabilities to meet the escalating demand for vaccines.

Outsourcing is becoming increasingly accepted as a viable and beneficial business model in the vaccine industry, driving the growth of the global vaccine contract manufacturing market. Additionally, the success of vaccine adjuvants companies is also driven by the growth of this market, as they develop innovative adjuvants for vaccine developers and manufacturers.

Key Market Segments

Type of Expression System Used

• Mammalian
• Microbial
• Others

Company Size

• Small
• Mid-sized
• Large / Very Large

Key Geographical Region

• North America
• Europe
• Asia-Pacific
• Rest of the World

Research Coverage:

• A comprehensive overview of vaccine contract manufacturing is presented, focusing on the diverse expression systems utilized in the development and manufacturing of vaccines. Furthermore, the overview provides a brief description of the principles and advantages of contract manufacturing, highlighting its increasing importance in the vaccine industry.
• A comprehensive analysis of the contract manufacturing landscape for vaccines is provided, including information on companies offering contract services, such as their year of establishment, company size, and location of headquarters. Additionally, this overview covers the types of services offered by these companies, including analytical testing, cell line development and virus banking, fill and finish, formulation development, process development, and regulatory consulting. The scale of operation is also examined, encompassing preclinical, clinical, and commercial stages. Furthermore, the overview explores the expression systems employed by these companies, including avian, insect, mammalian, microbial, and others. The review also delves into the types of vaccines manufactured by these companies, including live attenuated vaccines, inactivated vaccines, DNA vaccines, RNA-based vaccines (such as COVID-19 vaccines), subunit vaccines, toxoid-based vaccines, and others.
• A comprehensive analysis of the competitiveness of key players in the contract vaccine manufacturing industry is presented, focusing on a multi-faceted evaluation of their company strengths. This assessment considers factors such as the experience and reputation of the contract manufacturer, as well as their portfolio strength, which encompasses various elements including the scale of their operation, the range of vaccines they manufacture, the types of services they offer, their manufacturing capabilities, and the number of facilities they operate.
• Comprehensive profiles of the leading service providers in the vaccine contract manufacturing market, based in North America. Each profile features a brief overview of the vaccine contract manufacturing service provider, along with information on location of headquarters, year of establishment, number of employees, leadership team, service portfolio, recent developments, and an informed future outlook.
• An in-depth profiles of leading vaccine contract manufacturing service providers based in Europe are presented, providing a comprehensive overview of each company's strengths and capabilities. Each profile includes essential information such as the company's headquarters location, year of establishment, employee count, leadership team, service offerings, recent developments, and an expert forecast of future prospects. This detailed analysis enables a deeper understanding of the key players in the vaccine CMO market, their competitive positions, and their potential for growth and innovation.
• Comprehensive profiles of the leading service providers in the vaccine contract manufacturing market, based in Asia-Pacific. Each profile features a brief overview of the vaccine contract manufacturing service provider, along with information on location of headquarters, year of establishment, number of employees, leadership team, service portfolio, recent developments, and an informed future outlook.
• A thorough examination of the partnerships forged between industry stakeholders in the vaccine contract manufacturing sector is presented, based on a range of criteria. This analysis delves into the details of partnerships signed between since 2019, including the year of partnership, partnership type, therapeutic area, type of vaccine manufactured, and type of partner. Additionally, the report highlights the most active players in the industry, as measured by the number of partnerships they have signed during this period. The regional distribution of partnership activity is also mapped, providing a comprehensive understanding of the trends and dynamics driving collaboration in the vaccine contract manufacturing industry.
• A comprehensive examination of the expansion initiatives undertaken by vaccine contract manufacturers since 2020 is presented, analyzing various factors that influenced these developments. This analysis dissects the expansion initiatives based on key parameters, including the year of expansion, purpose of expansion (capacity expansion, capability expansion, new facility, geographical consolidation, and geographical expansion), location of the expanded facility, and investment amount. The report also identifies the most active players in the industry, measured by the number of expansion initiatives they have undertaken during this period. This in-depth analysis provides a detailed understanding of the strategic moves made by vaccine contract manufacturers to enhance their capabilities and expand their presence in the market.
• A comprehensive examination of the mergers and acquisitions that have shaped the vaccine contract manufacturing industry since 2018 is presented, analyzing various factors that influenced these deals. This analysis delves into the details of mergers and acquisitions based on key parameters, including the year of agreement, type of deal (merger, acquisition, joint venture, etc.), geographical location of the companies involved, type of acquisition (asset, equity, etc.), type of biologic manufactured, therapeutic area, and key value drivers. The report provides a thorough understanding of the strategic moves made by companies in the industry to expand their capabilities, gain market share, and enhance their competitiveness. By examining these deals, this analysis aims to identify trends and patterns in the industry's M&A landscape.
• A comprehensive estimate of the global vaccine manufacturing capacity is presented, based on publicly available data from industry stakeholders. The report highlights the distribution of available vaccine production capacity across various parameters, including company size (small, mid-sized, large, and very large firms), expression system used (mammalian, microbial, and others), and geographical region (North America, Europe, Asia-Pacific). This analysis provides a snapshot of the industry's current capacity landscape, enabling insights into the market share and competitive positioning of various vaccine manufacturers. By examining the distribution of capacity across different company sizes, expression systems, and regions, this report aims to shed light on the trends and patterns that shape the vaccine manufacturing industry.
• An informed estimates of the annual commercial and clinical demand for vaccines, based on key geographical regions.
• An insightful vendor selection framework analysis highlighting the parameters that should be considered while outsourcing operations to various vaccine manufacturing CMOs. The analysis was designed to enable stakeholder companies to evaluate a vendor for outsourcing their operations.
• Comprehensive analysis capturing the key parameters and trends that are likely to influence the future of vaccine contract manufacturing, under a SWOT framework.
• Comprehensive analysis of the factors that can impact the growth of vaccine contract manufacturing. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
• Comprehensive estimate of the current market size and the future market growth potential of the vaccine contract manufacturing market over the next decade. Based on multiple parameters, such as likely adoption trends and through reliable secondary and primary validations, we have provided an informed estimate on the market evolution during the forecast period till 2035. The report also features the likely distribution of the current and forecasted opportunity within the vaccine contract manufacturing industry. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the market growth.
• Comprehensive projections of the current and future opportunity for service providers in the vaccine CMO market across types of expression system used, namely mammalian, microbial and others.
• Comprehensive projections of the current and future opportunity for service providers in the vaccine contract manufacturing market across company size, namely small, mid-sized and large / very large.
• Detailed predictions of the current and future opportunity for service providers in the vaccine CMO market across different key geographical regions, namely North America, Europe, Asia-Pacific and rest of the world.

Key Benefits of Buying this Report

• The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
• Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
• The report provides stakeholders with a pulse on the Vaccine Contract Manufacturing Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

• AGC Biologics
• Bharat Biotech
• Biological E
• BioReliance
• Boehringer Ingelheim BioXcellence
• Catalent
• Charles River Laboratories
• Cobra Biologics
• Curia
• Eurofins Amatsigroup
• Eurogentec
• GreenPak Biotech
• Hong Kong Institute of Biotechnology
• IDT Biologika
• Lonza
• Meridian Life Sciences
• Syngene International
• WuXi Biologics
• Wockhardt

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databased and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Forecasted Estimates
  • 3.2.2. Currency Coverage
    • 3.2.2.1. Major Currencies Affecting the Market
    • 3.2.2.2. Impact of Currency Fluctuations on the Industry
  • 3.2.3. Foreign Exchange Impact
    • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
    • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 3.2.4. Recession
    • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 3.2.5. Inflation
    • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

• 4.1. Chapter Overview

5. INTRODUCTION

• 5.1. Chapter Overview
• 5.2. Classification of Vaccines based on Type of Active Ingredient
  • 5.2.1. Live, Attenuated Vaccines
  • 5.2.2. Inactivated Vaccines
  • 5.2.3. Subunit Vaccines
  • 5.2.4. Toxoid Vaccines
  • 5.2.5. DNA Vaccines
• 5.3. Key Components of Vaccine Formulations
• 5.4. Vaccine Development and Manufacturing
  • 5.4.1. Identification of Antigen and Manufacturing Process Development
  • 5.4.2. Production of Vaccines in Different Expression Systems
    • 5.4.2.1. Avian Expression Systems
    • 5.4.2.2. Bacterial Expression Systems
    • 5.4.2.3. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
    • 5.4.2.4. Insect Expression Systems
    • 5.4.2.5. Mammalian Expression Systems
    • 5.4.2.6. Plant Expression Systems
    • 5.4.2.7. Yeast Expression Systems
  • 5.4.3. Vaccine Manufacturing Process
    • 5.4.3.1. Upstream Process
    • 5.4.3.2. Downstream Process
    • 5.4.3.3. Formulation and Fill / Finish
  • 5.4.4. Clinical Development and Approval
  • 5.4.5. Vaccine Supply Chain and Logistics
• 5.5. Vaccine Contract Manufacturing
  • 5.5.1. Need for Outsourcing Vaccine Manufacturing Operations
  • 5.5.2. Commonly Outsourced Operations
  • 5.5.3. Selecting a Contract Manufacturing Partner
  • 5.5.4. Advantages of Outsourcing Manufacturing Operations
  • 5.5.5. Risks and Challenges Associated with Contract Manufacturing
• 5.6. Future Perspectives

6. MARKET LANDSCAPE

• 6.1. Chapter Overview
• 6.2. Vaccine Contract Manufacturers: Overall Market Landscape
  • 6.2.1. Analysis by Year of Establishment
  • 6.2.2. Analysis by Company Size
  • 6.2.3. Analysis by Location of Headquarters
  • 6.2.4. Analysis by Type of Service Offered
  • 6.2.5. Analysis by Scale of Operation
  • 6.2.6. Analysis by Type of Expression System Used
  • 6.2.7. Analysis by Type of Vaccine Manufactured

7. COMPANY COMPETITIVENESS ANALYSIS

• 7.1. Chapter Overview
• 7.2. Assumptions And Key Parameters
• 7.3. Methodology
• 7.4. Company Competitiveness Analysis: Vaccine Contract Manufacturers in North America
• 7.5. Company Competitiveness Analysis: Vaccine Contract Manufacturers in Europe
• 7.6. Company Competitiveness Analysis: Vaccine Contract Manufacturers in Asia-Pacific
• 7.7. Company Competitiveness Analysis: Vaccine Contract Manufacturers in Rest of the World

8. COMPANY PROFILES: VACCINE CONTRACT MANUFACTURERS IN NORTH AMERICA

• 8.1. Chapter Overview
• 8.2. AGC Biologics
  • 8.2.1. Company Overview
  • 8.2.2. Recent Developments and Future Outlook
• 8.3. Bioreliance
  • 8.3.1. Company Overview
  • 8.3.2. Recent Developments and Future Outlook
• 8.4. Catalent
  • 8.4.1. Company Overview
  • 8.4.2. Recent Developments and Future Outlook
• 8.5. Charles River Laboratories
  • 8.5.1. Company Overview
  • 8.5.2. Recent Developments and Future Outlook
• 8.6. Curia
  • 8.6.1. Company Overview
  • 8.6.2. Recent Developments and Future Outlook
• 8.7. Meridian Life Science
  • 8.7.1. Company Overview
  • 8.7.2. Recent Developments and Future Outlook

9. COMPANY PROFILES: VACCINE CONTRACT MANUFACTURERS IN EUROPE

• 9.1. Chapter Overview
• 9.2. Boehringer Ingelheim BioXcellence
  • 9.2.1. Company Overview
  • 9.2.2. Recent Developments and Future Outlook
• 9.3. Eurofins Amatsigroup
  • 9.3.1. Company Overview
  • 9.3.2. Recent Developments and Future Outlook
• 9.4. Eurogentec
  • 9.4.1. Company Overview
  • 9.4.2. Recent Developments and Future Outlook
• 9.5. IDT Biologika
  • 9.5.1. Company Overview
  • 9.5.2. Recent Developments and Future Outlook
• 9.6. Lonza
  • 9.6.1. Company Overview
  • 9.6.2. Recent Developments and Future Outlook

10. COMPANY PROFILES: VACCINE CONTRACT MANUFACTURERS IN ASIA-PACIFIC

• 10.1. Chapter Overview
• 10.2. Bharat Biotech
  • 10.2.1. Company Overview
  • 10.2.2. Recent Developments and Future Outlook
• 10.3. Biological E
  • 10.3.1. Company Overview
  • 10.3.2. Recent Developments and Future Outlook
• 10.4. GreenPak Biotech
  • 10.4.1. Company Overview
  • 10.4.2. Recent Developments and Future Outlook
• 10.5. Hong Kong Institute of Biotechnology
  • 10.5.1. Company Overview
  • 10.5.2. Recent Developments and Future Outlook
• 10.6. Syngene International
  • 10.6.1. Company Overview
  • 10.6.2. Recent Developments and Future Outlook
• 10.7. Wockhardt
  • 10.7.1. Company Overview
  • 10.7.2. Recent Developments and Future Outlook
• 10.8. WuXi Biologics
  • 10.8.1. Company Overview
  • 10.8.2. Recent Developments and Future Outlook

11. PARTNERSHIPS AND COLLABORATIONS

• 11.1. Chapter Overview
• 11.2. Partnership Model
• 11.3. Vaccine Contract Manufacturers: Partnerships and Collaborations
  • 11.3.1. Analysis by Year of Partnership
  • 11.3.2. Analysis by Type of Partnership
  • 11.3.3. Analysis by Year and Type of Partnership
  • 11.3.4. Analysis by Therapeutic Area
  • 11.3.5. Most Active Players: Analysis by Number of Partnerships
  • 11.3.6. Analysis by Geography
    • 11.3.6.1. Intracontinental and Intercontinental Agreements
    • 11.3.6.2. International and Local Deals

12. RECENT EXPANSIONS

• 12.1. Chapter Overview
• 12.2. Vaccine Contract Manufacturers: Recent Expansions
  • 12.2.1. Analysis by Year of Expansion
  • 12.2.2. Analysis by Purpose of Expansion
  • 12.2.3. Analysis by Year and Purpose of Expansion
  • 12.2.4. Analysis by Location of Expanded Facility
  • 12.2.5. Analysis by Purpose of Expansion and Location of Expanded Facility
  • 12.2.6. Analysis by Amount Invested
  • 12.2.7. Most Active Players: Analysis by Number of Recent Expansions

13. MERGERS AND ACQUSITIONS

• 13.1. Chapter Overview
• 13.2. Merger and Acquisition Models
• 13.3. Vaccine Contract Manufacturing: Mergers and Acquisitions
  • 13.3.1. Analysis by Year of Agreement
  • 13.3.2. Analysis by Type of Agreement
  • 13.3.3. Analysis by Geography
    • 13.3.3.1. Intercontinental and Intracontinental Agreements
    • 13.3.3.2. Local and International Agreements
  • 13.3.4. Year-wise Trend in Key Geographies
  • 13.3.5. Most Active Players: Analysis by Number of Agreements
• 13.4. Concluding Remarks

14. CAPACITY ANALYSIS

• 14.1. Chapter Overview
• 14.2. Assumptions and Methodology
• 14.3. Vaccine Contract Manufacturing: Global Installed Capacity
  • 14.3.1. Analysis by Company Size
  • 14.3.2. Analysis by Type of Expression System Used
  • 14.3.3. Analysis by Location of Manufacturing Facility
• 14.4. Concluding Remarks

15. DEMAND ANALYSIS

• 15.1. Chapter Overview
• 15.2. Assumptions and Methodology
• 15.3. Global Demand for Vaccines
  • 15.3.1. Global Clinical Demand for Vaccines
  • 15.3.2. Global Commercial Demand for Vaccines
• 15.4. Analysis by Geography
• 15.5. Global Clinical Demand for COVID-19 Vaccines
• 15.6. Global Commercial Demand for COVID-19 Vaccines

16. VENDOR SELECTION FRAMEWORK ANALYSIS

• 16.1. Chapter Overview
• 16.2. Reasons to Outsource in Vaccine Manufacturing
• 16.3. Commonly Outsourced Operations in Vaccine Manufacturing
• 16.4. Key Parameters
• 16.5. Methodology
• 16.6. Comparison of Parameters
• 16.7. Value Addition vs Evaluation Complexity Matrix
• 16.8. Case Study Assessment of Leading Players
• 16.9. Overview of Vendor Assessment Dashboard
  • 16.9.1. Scenario I
  • 16.9.2. Scenario II
  • 16.9.3. Scenario III
• 16.10. Concluding Remarks

17. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET

• 17.1. Chapter Overview
• 17.2. Key Assumptions and Methodology
• 17.3. Global Vaccine Contract Manufacturing Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 17.3.1. Scenario Analysis
    • 17.3.1.1. Conservative Scenario
    • 17.3.1.2. Optimistic Scenario
• 17.4. Key Market Segmentation
• 17.5. Global COVID-19 Contract Manufacturing Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

18. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, BY TYPE OF EXPRESSION SYSTEM USED

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. Vaccine Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, 2024 and 2035
  • 18.3.1. Vaccine Contract Manufacturing Market for Mammalian Expression Systems: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • 18.3.2. Vaccine Contract Manufacturing Market for Microbial Expression Systems: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • 18.3.3. Vaccine Contract Manufacturing Market for Other Expression Systems: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
• 18.4. Data Triangulation and Validation

19. VACCINE CONTRACT MANUFACTURING MARKET, BY COMPANY SIZE

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Vaccine Contract Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
  • 19.3.1. Vaccine Contract Manufacturing Market for Small Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.3.2. Vaccine Contract Manufacturing Market for Mid-sized Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.3.3. Vaccine Contract Manufacturing Market for Large and Very Large Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
• 19.4. Data Triangulation and Validation

20. VACCINE CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Vaccine Contract Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
  • 20.3.1. Vaccine Contract Manufacturing Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.1.1. Vaccine Contract Manufacturing Market in US: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.1.2. Vaccine Contract Manufacturing Market in Canada: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.1.3. Vaccine Contract Manufacturing Market in Rest of North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.1.4. Vaccine Contract Manufacturing Market for Mammalian Expression System in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.1.5. Vaccine Contract Manufacturing Market for Microbial Expression System in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.1.6. Vaccine Contract Manufacturing Market for Other Expression System t in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.1.7. Vaccine Contract Manufacturing Market for Small Companies in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.1.8. Vaccine Contract Manufacturing Market for Mid-sized Companies in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.1.9. Vaccine Contract Manufacturing Market for Large / Very Large Companies in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • 20.3.2. Vaccine Contract Manufacturing Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.2.1. Vaccine Contract Manufacturing Market in Germany: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.2.2. Vaccine Contract Manufacturing Market in UK: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.2.3. Vaccine Contract Manufacturing Market in France: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.2.4. Vaccine Contract Manufacturing Market in Italy: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.2.5. Vaccine Contract Manufacturing Market in Spain: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.2.6. Vaccine Contract Manufacturing Market in Rest of Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.2.7. Vaccine Contract Manufacturing Market for Mammalian Expression System in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.2.8. Vaccine Contract Manufacturing Market for Microbial Expression System in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.2.9. Vaccine Contract Manufacturing Market for Other Expression System in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.2.10. Vaccine Contract Manufacturing Market for Small Companies in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.2.11. Vaccine Contract Manufacturing Market for Mid-sized Companies in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.2.12. Vaccine Contract Manufacturing Market for Large / Very Large Companies in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • 20.3.3. Vaccine Contract Manufacturing Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.3.1. Vaccine Contract Manufacturing Market in China: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.3.2. Vaccine Contract Manufacturing Market in India: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.3.3. Vaccine Contract Manufacturing Market in Japan: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.3.4. Vaccine Contract Manufacturing Market in Rest of Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.3.5. Vaccine Contract Manufacturing Market for Mammalian Expression System in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.3.6. Vaccine Contract Manufacturing Market for Microbial Expression System in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.3.7. Vaccine Contract Manufacturing Market for Other Expression System in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.3.8. Vaccine Contract Manufacturing Market for Small Companies in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.3.9. Vaccine Contract Manufacturing Market for Mid-sized Companies in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.3.10. Vaccine Contract Manufacturing Market for Large / Very Large Companies in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • 20.3.4. Vaccine Contract Manufacturing Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
• 20.4. Data Triangulation and Validation

21. FUTURE GROWTH OPPORTUNITIES

• 21.1. Chapter Overview
• 21.2. Technological Advancements to Drive Growth in Vaccine Manufacturing Industry
• 21.3. Shift to Single-Use Systems and Components for Vaccine Manufacturing
• 21.4. The Advent of Virus-like Particles (VLPs)
• 21.5. Growing Investments in Existing Infrastructure
• 21.6. Evolving Client / Sponsor and CMO / CDMO Relationships
• 21.7. Business Acquisition and Consolidation Activity

22. SWOT ANALYSIS

• 22.1. Chapter Overview
• 22.2. Strengths
• 22.3. Weaknesses
• 22.4. Opportunities
• 22.5. Threats
• 22.6. Comparison of SWOT Factors

23. CONCLUDING REMARKS

24. EXECUTIVE INSIGHTS

• 24.1. Chapter Overview
• 24.2. Menzo Havenga, Chief Executive Officer and Claire Otjes, Marketing Manager, Batavia Biosciences
• 24.3. Dietmar Katinger, Chief Executive Officer, Polymun Scientific
• 24.4. David C Cunningham, Director Corporate Development, Goodwin Biotechnology
• 24.5. Ingrid Kromann, Ex-Director of Vaccine Development, Statens Serum Institute
• 24.6. Kevin Daley, Director Pharmaceuticals, Novasep Synthesis
• 24.7. Thilo Kamphausen, Director Business Development, Richer-Helm BioLogics
• 24.8. Sebastian Schuck, Head of Business Development, Wacker Biotech
• 24.9. Oliver Schub, Senior Business Development Manager, ProBioGen

25. APPENDIX 2: TABULATED DATA

26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

관련자료